Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 1464859)

1.

Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor.

Roubenoff R, Roubenoff RA, Ward LM, Holland SM, Hellmann DB.

J Rheumatol. 1992 Oct;19(10):1505-10.

PMID:
1464859
2.

Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor.

Engvall IL, Elkan AC, Tengstrand B, Cederholm T, Brismar K, Hafstrom I.

Scand J Rheumatol. 2008 Sep-Oct;37(5):321-8. doi: 10.1080/03009740802055984.

PMID:
18666027
3.

Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.

Metsios GS, Stavropoulos-Kalinoglou A, Douglas KM, Koutedakis Y, Nevill AM, Panoulas VF, Kita M, Kitas GD.

Rheumatology (Oxford). 2007 Dec;46(12):1824-7.

4.

Rheumatoid cachexia, central obesity and malnutrition in patients with low-active rheumatoid arthritis: feasibility of anthropometry, Mini Nutritional Assessment and body composition techniques.

Elkan AC, Engvall IL, Cederholm T, Hafström I.

Eur J Nutr. 2009 Aug;48(5):315-22. doi: 10.1007/s00394-009-0017-y. Epub 2009 Mar 31.

PMID:
19333642
5.

Tumor necrosis factor-alpha production is associated with less body cell mass in women with rheumatoid arthritis.

Walsmith J, Abad L, Kehayias J, Roubenoff R.

J Rheumatol. 2004 Jan;31(1):23-9.

PMID:
14705214
6.

Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis.

Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ.

Am J Clin Nutr. 2006 Dec;84(6):1463-72.

7.
8.

Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation.

Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, Dinarello CA, Rosenberg IH.

J Clin Invest. 1994 Jun;93(6):2379-86.

9.
12.
13.

A close association of body cell mass loss with disease activity and disability in Chinese patients with rheumatoid arthritis.

Chen YM, Chen HH, Hsieh CW, Hsieh TY, Lan JL, Chen DY.

Clinics (Sao Paulo). 2011;66(7):1217-22.

14.

Tumor necrosis factor-alpha serum activity during treatment of acute decompensation of cachectic and non-cachectic patients with advanced congestive heart failure.

Parissis JT, Venetsanou KF, Mentzikof DG, Ziras NG, Kefalas CG, Karas SM.

Scand Cardiovasc J. 1999;33(6):344-50.

PMID:
10622546
15.

Rheumatoid cachexia: a clinical perspective.

Summers GD, Deighton CM, Rennie MJ, Booth AH.

Rheumatology (Oxford). 2008 Aug;47(8):1124-31. doi: 10.1093/rheumatology/ken146. Epub 2008 Apr 30. Review.

17.

A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analog iloprost: cytokine modulation, safety, and clinical effects.

Gao IK, Scholz P, Boehme MW, Norden C, Lemmel EM.

Rheumatol Int. 2002 Jun;22(2):45-51. Epub 2002 May 3.

PMID:
12070674
18.

Abnormal vitamin B6 status in rheumatoid cachexia. Association with spontaneous tumor necrosis factor alpha production and markers of inflammation.

Roubenoff R, Roubenoff RA, Selhub J, Nadeau MR, Cannon JG, Freeman LM, Dinarello CA, Rosenberg IH.

Arthritis Rheum. 1995 Jan;38(1):105-9.

PMID:
7818558
19.
20.

[Tumor necrosis factor-alpha and kidney damage in rheumatoid arthritis].

Tsybul'ko SV, Baranov AA, Borodin AG, Korshunov NI, Kirdianov SIu.

Ter Arkh. 2001;73(5):8-11. Russian.

PMID:
11517757
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk